The phosphatidylinositol-3 kinase or PI3K signaling pathway has been identified as a valid target in a large number of cancers. It is probably one of the most important pathways in cancer metabolism and growth. Mutations in the PI3K pathway are frequent in breast cancer, ovarian and endometrial cancers, causing resistance to human epidermal growth factor receptor 2–targeted agents and, possibly, to hormonal agents as well. Available agents that affect the PI3K pathway include monoclonal… Continue
Added by Peter Hofland, PhD on January 23, 2013 at 1:30pm —
About 5% of all breast cancers are attributed to an inherited mutation in one of two cancer susceptibility genes, BRCA1 and BRCA2. Researchers how now developed a new multiple gene expression profile test was able to predict the presence of either BRCA1 or BRCA2 mutations in otherwise healthy women carrying the mutations, according to data published in Cancer Prevention Research, a… Continue
Added by Peter Hofland, PhD on January 22, 2013 at 6:00pm —
Treatment with a recombinant poxviral vaccine showed a positive response in both metastatic breast cancer and ovarian cancer, according to a trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR)the world’s oldest and largest professional organization dedicated to advancing cancer research. Continue
“With this vaccine, we can clearly generate immune responses…
Added by Peter Hofland, PhD on November 12, 2011 at 4:24pm —
The European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Bevacizumab (Avastin, Genentech/… Continue
Added by Peter Hofland, PhD on September 23, 2011 at 12:30am —
A randomized, multicenter screening study of nearly 80,000 women in the general population showed that using a CA-125 blood test and transvaginal ultrasound for early detection of ovarian cancer did not reduce the risk of dying from the disease, and resulted in a large number of false positives and related biopsies and follow-up procedures.
The results,which will be presented at the 47th Annual Meeting of the… Continue
Added by Peter Hofland, PhD on June 3, 2011 at 6:00pm —
A paper published in the June 2011 issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than a physician's preoperative assessment alone. The study is the second published online this month in the journal, which is the… Continue
Added by Peter Hofland, PhD on May 24, 2011 at 6:30am —
Two new studies highlight the power of sequencing cancer patients’ genomes as a diagnostic tool, helping doctors decide the best course of treatment and researchers identify new cancer-susceptibility mutations that can be passed from parent to child.
Both studies, by Washington University School of Medicine researchers at the Siteman Cancer Center
, are reported April 20 in the… Continue
Added by Peter Hofland, PhD on April 20, 2011 at 10:30pm —
Women with ovarian cancer who have the BRCA2 gene mutation are more likely to survive the malignancy than women with the BRCA1 mutation, or women without either mutation. In results presented at the 102nd Annual Meeting of the American Association for Cancer Research, held April 2-6, 2011 at the Orange County Convention Center in Orlando, Florida, Kelly Bolton, a fellow at the National Cancer Institute, said the findings describe… Continue
Added by Peter Hofland, PhD on April 4, 2011 at 1:00pm —
Results from the OCEANS Study, a phase III study evaluating bevacizumab (Avastin®, F. Hoffmann-La Roche Ltd) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
Added by Peter Hofland, PhD on February 8, 2011 at 11:30am —
Women planning on taking hormone therapy for the treatment of menopausal symptoms should be aware of a possible increased risk for ovarian cancer, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held in Philadelphia from November 7-10, 2010. Continue
“This study is consistent with previous recommendations that say if women are going to take hormones they should only take them in the short term,” said…
Added by Peter Hofland, PhD on November 9, 2010 at 10:30pm —
Researchers from Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have found that as many as 50% of young girls treated for germ-cell ovarian tumors might safely be spared chemotherapy using a "watch and wait" strategy to determine if the follow-up treatment is needed.
In contrast… Continue
Added by Peter Hofland, PhD on October 22, 2010 at 1:30pm —
Early results from a large Phase-III trial suggest that adding bevacizumab (Avastin®, Genentech) to chemotherapy as a treatment for newly diagnosed ovarian cancer reduces the risk of disease progression during the first year of treatment.
At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Tim… Continue
Added by Peter Hofland, PhD on October 11, 2010 at 6:30am —
An investigational drug, AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase-II trial involving 161 patients with recurrent ovarian cancer. The updated results, now including data on overall survival, are being presented in a poster discussion at the 35th European Society for Medical Oncology (ESMO) Congress being held in Milan, Italy. (Abstract Number: 975PD)
"Treatment advances in ovarian cancer are desperately needed.… Continue
Added by Peter Hofland, PhD on October 9, 2010 at 9:30am —
The Gynecologic Oncology Group (GOG), a national non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies, intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with Reolysin® in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer… Continue
Added by Peter Hofland, PhD on September 2, 2010 at 4:30am —
“Advancing Quality Through Innovation,” the theme of the 46th Annual Meeting the American Society of Clinical Oncology (ASCO), being held from June 4-June 8, 2010, at McCormick Place in Chicago, demonstrates the progress made in understanding cancer and how new therapies many benefit patients today and in the future. The meeting is expected to draw approximately 30,000 cancer specialists.
“Our growing understanding of cancer’s complex behavior is being… Continue
Added by Peter Hofland, PhD on May 20, 2010 at 11:30pm —
The U.S. Food and Drug Administration (FDA) today cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.
OVA1 identifies some women who will benefit from referral to a gynecological oncologist for their surgery, despite negative results from other clinical and radiographic tests for ovarian… Continue
Added by Peter Hofland, PhD on September 11, 2009 at 10:10pm —